<code id='DCB5F920FF'></code><style id='DCB5F920FF'></style>
    • <acronym id='DCB5F920FF'></acronym>
      <center id='DCB5F920FF'><center id='DCB5F920FF'><tfoot id='DCB5F920FF'></tfoot></center><abbr id='DCB5F920FF'><dir id='DCB5F920FF'><tfoot id='DCB5F920FF'></tfoot><noframes id='DCB5F920FF'>

    • <optgroup id='DCB5F920FF'><strike id='DCB5F920FF'><sup id='DCB5F920FF'></sup></strike><code id='DCB5F920FF'></code></optgroup>
        1. <b id='DCB5F920FF'><label id='DCB5F920FF'><select id='DCB5F920FF'><dt id='DCB5F920FF'><span id='DCB5F920FF'></span></dt></select></label></b><u id='DCB5F920FF'></u>
          <i id='DCB5F920FF'><strike id='DCB5F920FF'><tt id='DCB5F920FF'><pre id='DCB5F920FF'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:67
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Attacks on the drug industry will lead to fewer breakthroughs
          Attacks on the drug industry will lead to fewer breakthroughs

          TedW.Love,sittingintheplaidshirt,withhisfamilyin1964CourtesyTedLoveIwasborninAlabamaintheJimCrowSout

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Living with Hashimoto's and celiac disease, and med school, too

          BriannaCelix:Havingtwoautoimmunediseasesis"my‘why’formedicine."Photoillustration:CaseySheneryforSTAT